Mode
Text Size
Log in / Sign up
N/A N=367

Programme of Acromegaly Screening in Patients With Associated Somatic Disorders

Acromegaly

Enrolled (actual)
367
Serious AEs
Results posted
Apr 2021
Primary outcome: Primary: Percentage of Participants Diagnosed With Acromegaly — 5.8; 2.4 percentage of participants

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Non-interventional cross-sectional survey (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Ipsen
Primary completion
Sep 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Percentage of Participants Diagnosed With Acromegaly
5.8; 2.4
SECONDARY
Number of Participants Diagnosed With Acromegaly Using Biochemical Assays (IGF-1, GH, OGTT) and Instrumental Examination Methods (MRI)
19; 8
SECONDARY
Percentage of Participants With Associated Concurrent Somatic Disorders
22.2; 3.8; 100.0; 56.9; 100.0; 71.9
SECONDARY
Percentage of Participants With Microadenomas and Macroadenomas
0.3; 2.1; 2.7; 94.8
SECONDARY
Percentage of Participants With the Most Pathognomonic Subjective and Objective Signs for Tracing Acromegaly
0; 0; 2.74; 97.26; 1.52; 10.94 0.0196 sig

Summary

The primary objective of the protocol is to define percentage of patients with acromegaly in relation to the total number of screened patients with confirmed clinically significant set of associated somatic disorders with the help of laboratory (Insulin-like Growth Factor I, Growth Hormone, Oral Glucose-Tolerance Test [IGF-1, GH, OGTT]) and instrumental examination methods (Magnetic Resonance Imaging [MRI]).

Eligibility Criteria

Inclusion Criteria

  • Men and women aged 18 years and above with associated somatic disorders observed at the Moscow Endocrinology dispensary or Endocrinology Hospital at First Moscow State Medical University
  • Patients who signed the Informed Consent Form for participation in the survey before collection of any information.

Exclusion Criteria

  • Patient already diagnosed with acromegaly
  • Patient's refusal to participate in the survey.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02020967). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search